There was a problem loading this presentation. You may not have permission to view it.

You do not have permission to view this presentation.

Is switching treatments from PDE5 inhibitors to riociguat an option in patients with PAH?

OK

An error occurred while loading this content.

Please refresh the page to try again.

Refresh Now
>>
<<
 
You previously started this content
Replay
Resume
 
Login or join to view
Click to Play
 

Is switching treatments from PDE5 inhibitors to riociguat an option in patients with PAH?

Prof. Dr. med. Marius Hoeper
Department of Pneumology, Medical School Hanover
 
 

In this short presentation Prof. Hoeper explains whether riociguat is an option in PAH treatment for patients with an insufficient response to PDE-5 inhibitors.